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Context: Clinical trials have demonstrated the efficacy and safety of the
capsaicin 8% patch in patients with peripheral neuropathic pain (PNP);
however, few studies have assessed this treatment in a clinical practice.
Objective: To determine whether treatment and re-treatment with the
capsaicin 8% patch reduce PNP intensity in clinical practice.
Methods: Three non-interventional, observational studies were
concurrently conducted in Denmark, Norway and Sweden. Patients with
probable or definite PNP received one or two treatments with the
capsaicin 8% patch according to usual clinical practice. All analyses were
performed on combined data.
Results: Overall, 382 and 181 patients received treatment and re-
treatment, respectively, with the capsaicin 8% patch. At the group level,
a significant reduction in mean level of ‘usual pain’ intensity (Numerical
Pain Rating Scale) over the last 24 h’ score was observed from baseline
to Weeks 2 through 8 [1.05 (95% confidence interval: 1.27, 0.82);
p < 0.001] with 28% and 31% of patients reporting a ≥30% reduction
in pain after first treatment and re-treatment, respectively.
Improvements in health-related quality of life (EQ-5D-3L index) and
overall health status (Patient Global Impression of Change) were
observed early (Week 1) and throughout the treatment periods. Most
application site reactions subsided within a week after treatment.
Following treatment and re-treatment, 57% and 71% of patients,
respectively, were willing to undergo further treatment with the
capsaicin 8% patch.
Conclusion: In Scandinavian clinical practice, capsaicin 8% patch
treatment was associated with significant reductions in pain intensity
and was well tolerated with over half of patients willing to undergo re-
treatment.
1. Introduction
Neuropathic pain is defined as pain due to a lesion
or disease of the somatosensory nervous system
[International Association for the Study of Pain
(IASP), 2012]. Peripheral neuropathic pain may
manifest itself in a number of aetiologies, including
traumatic nerve injury, radiculopathy, polyneuropa-
thy and after herpes zoster (Finnerup et al., 2015).
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Commonly used pharmacological treatments include
antidepressants, anticonvulsants, topical lidocaine
and opioids. These treatments, however, are limited
by central nervous system adverse effects, such as
somnolence and dizziness, and for the latter, the
potential for drug dependence (Attal et al., 2010;
Finnerup et al., 2010, 2015; Tesfaye et al., 2011;
Smith et al., 2012; Gahr et al., 2013). In addition,
current evidence indicates that less than half of
patients with neuropathic pain obtain sufficient pain
relief with current systemic analgesics (Finnerup
et al., 2010).
Capsaicin is a highly selective agonist of the
TRPV1 receptor of the A delta and C fibres. Activa-
tion of TRPV1-expressing nociceptors leads to
defunctionalization of TRPV1-containing sensory
axons, and reversible retraction of epidermal and
dermal nerve fibres, followed by inhibition of
excitability after a single treatment (Szallasi and
Blumberg, 1999; Kennedy et al., 2010; Anand and
Bley, 2011). The capsaicin 8% patch is designed to
rapidly deliver a high concentration of capsaicin to
epidermal nerve endings and is indicated for the
treatment of peripheral neuropathic pain (PNP) in
adults either alone or in combination with other
medicinal products for pain (European Medicines
Agency, 2015). The clinical efficacy and safety of this
patch have been documented in a comprehensive
phase II and III clinical development programme,
showing sustained and clinically relevant pain relief
after a single application (Backonja et al., 2008;
Simpson et al., 2008, 2016; Irving et al., 2011; Clif-
ford et al., 2012; Vinik et al., 2016). A meta-analysis
of seven randomized controlled clinical studies of
single application of capsaicin 8% patch for the
treatment of PHN and HIV-associated PNP showed
that almost half of the patients achieved a ≥30%
reduction in pain intensity within 12 weeks, which
was significantly superior to controls (Mou et al.,
2014). A recent study showed that the number
needed to treat to achieve a 50% reduction in pain
was 10.6 (Finnerup et al., 2015). The outcomes of
single applications of the capsaicin 8% patch for the
treatment of PNP have been documented in clinical
practice (Maihofner and Heskamp, 2013, 2014;
Haanpaa et al., 2016), and recently, repeat applica-
tions were found to be effective and well tolerated
in a 52-week real-world European study (Man-
kowski et al., 2017).
The main aim of this combined analysis of three
non-interventional, observational studies, performed
in Norway, Sweden and Denmark, was to investigate
patient’s PNP intensity following treatment and
re-treatment with the capsaicin 8% patch in Scandi-
navian clinical practice. Here we report the effective-
ness, tolerability, patient-reported health-related
quality of life (HRQoL), concomitant use of medica-
tions due to PNP and the willingness to receive
additional treatment(s) following treatment and re-
treatment with the capsaicin 8% patch.
2. Materials and methods
2.1 Study design and participants
Three prospective, non-interventional, observational
studies with identical protocols were concurrently
conducted between November 2010 and September
2012 in Denmark, Norway and Sweden in accor-
dance with the principles of the Declaration of Hel-
sinki, International Conference on Harmonization
guidelines and local ethical and legal requirements.
Patients were eligible for inclusion if they were
≥18 years old; had probable or definite PNP in accor-
dance with Treede et al., 2008 (Treede et al., 2008);
and had provided written informed consent. Patients
diagnosed with PNP due to partial nerve damage,
and patients with amputations suffering from resid-
ual limb pain, suggesting active afferent nerves, were
allowed to enter the studies. Patients with phantom
limb pain (total deafferentation pain) only were not
included, as this pain is not considered responsive to
local capsaicin treatment. Exclusion criteria included:
previous treatment with the capsaicin 8% patch;
PNP due to total deafferentation; unlikely or possible
PNP (Treede et al., 2008); facial pain; diabetic PNP;
or unsuitability for treatment with the capsaicin 8%
patch (based on the discretion of the treating physi-
cian).
2.2 Treatment
The capsaicin 8% patch [QUTENZATM cutaneous
patch (capsaicin 179 cutaneous patch (capsaicin 179
mg, 8% w/w), supplied by Astellas Pharma Europe
B.V., Leiden, The Netherlands] was applied, as direc-
ted in the summary of product characteristics (Euro-
pean Medicines Agency, 2015). At each treatment
visit, the size of the application area was assessed,
and the severity of the application site reaction and
pain intensity was recorded. A maximum of four
patches were allowed per treatment. The patch
application time was 30 min on the feet and 60 min
on other parts of the body (Simpson et al., 2008).
After treatment, there was an option of up to six
additional follow-up contacts with the clinic as
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deemed necessary by the investigator and/or patient
(Table 1). No pre-treatment assessments were carried
out prior to re-treatment. Re-treatment was offered
at the physician’s discretion, at the recommended
interval of ≥90 days after the previous treatment,
consistent with the summary of product characteris-
tics (European Medicines Agency, 2015). Patients
were followed for up to 3 months after each treat-
ment.
2.3 Assessments
2.3.1 Effectiveness and tolerability
Patients were assessed by their treating physician or
a study nurse. The Numerical Pain Rating Scale
(NPRS) [ranging from 0 (no pain) to 10 (worst imag-
inable pain)] (Farrar et al., 2001) was used to assess
‘usual level pain score for the past 24 h’ (herein
referred to as NPRS ‘usual’ pain), pain intensity
‘right now’ and the ‘lowest’ and ‘highest’ level of
pain intensity over the last 24 h. HRQoL was
assessed by the EuroQol five dimensions 3 level
questionnaire (EQ-5D-3L) (Rabin and de Charro,
2001). The Patient Global Impression of Change
(PGIC) questionnaire was used to measure changes
in patients’ overall health status compared to before
treatment (Hurst and Bolton, 2004).
The primary effectiveness endpoint was the mean
change in pain intensity, evaluated by mean NPRS
‘usual’ pain, from first treatment baseline to the
mean average of all values observed between Weeks
2 and 8. The change in the mean NPRS ‘usual’ pain
score from baseline (before patch application at
treatment visit) to Weeks 2 through 8 was also
assessed following re-treatment. Data from the clos-
ing visit in the first treatment period (Week 12) were
used as baseline for the re-treatment period (herein
referred to as re-treatment baseline). At the final fol-
low-up contact of the first and second treatment
periods, patients were asked whether they would be
willing to undergo re-treatment with the capsaicin
8% patch. Other secondary effectiveness endpoints
for first treatment and re-treatment included the
proportion of patients with a ≥30%, ≥50% or ≥2
units reduction in mean NPRS ‘usual’ pain score
from first treatment baseline and re-treatment base-
line to Weeks 2 through 8 and to Weeks 2 through
12, respectively. Additional secondary endpoints
were: time to re-treatment; change in overall health
status using the PGIC questionnaire at each assess-
ment; change in the EQ-5D-3L health score from
first treatment baseline and re-treatment baseline to
each assessment; change in the size of the painful
area (decreased, increased, unchanged) from first
treatment baseline and re-treatment baseline to each
assessment; change in the use of concomitant medi-
cations due to PNP from baseline to each assessment;
willingness to undergo re-treatment; tolerability (ap-
plication site reactions; treatment-related effects
[NPRS pain ‘right now’] from first treatment baseline
and re-treatment baseline to each assessment; use of
rescue medications).
Treatment-related effects were recorded as mild
(no impact on the patient), moderate (has impact on
the patient, but tolerable) or severe (has impact on
the patient’s daily living and the patient received
treatment against the application site reaction).








Visit 2 Week 2 Week 4 Week 8 Week 12
Days from patch applicationa 3  3 3  3 14  7 30 + 15/8 60  14 90 + 30/15
Assessment
NPRS ‘pain now’b U U U U U U U
NPRS ‘usual’ painc U U U U U U
EQ-5D-3L U U U U U U
PGIC U U U U U
Concomitant medication U U U U U U
Size of application area and patch U U
Severity of application site reaction U U U U
Size of painful aread U U U U U
EQ-5D-3L, EuroQol five dimensions 3 level questionnaire NPRS, Numerical Pain Rating Scale; PGIC, Patient Global Impression of Change.
aThe timing of the follow-up contacts was determined by the established practice of each centre and patient requirements.
bPain intensity due to patch application.
cPain over the last 24 h.
dThe baseline size of the pain area was the size of the patch applied at the first visit of each treatment.
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Adverse events were reported by centres in accor-
dance with routine practice for spontaneous adverse
event reporting. Due to the non-interventional nat-
ure of the three studies, intense patient follow-up
was not possible.
2.4 Statistical methods
Statistical power was not determined due to the
non-interventional nature of the studies. The study
protocol estimated that a total of approximately 400
patients (200 in Sweden and 100 each in Denmark
and Norway, respectively) would be included in the
three studies. As the three studies shared a common
design and were performed concurrently, patients
likely had similar baseline demographic characteris-
tics, and the complementary effectiveness data from
the individual studies provided sufficient justification
for pooling study data. The data presented are the
post hoc, pooled results from these three studies.
Descriptive statistics were used for presenting age,
number of concomitant neuropathic pain medica-
tions, NPRS pain levels, size of the treatment area at
baseline and tolerability. Time to re-treatment was
calculated using the Kaplan–Meier method.
Numerical Pain Rating Scale scores observed dur-
ing the first 13 days following first treatment were
not included in the primary analysis due to the
potential bias from anaesthesia and analgesia pre-
treatment and possible use of rescue medication.
Analysis of covariance (ANCOVA) was used for the
primary analysis to test for influential baseline char-
acteristics (including sex, age, certainty of PNP diag-
nosis, PNP aetiology and NPRS pain) and for
country, using a significance level of p ≤ 0.05. For
responder endpoints (≥30%, ≥50% or ≥2 units
reduction in mean NPRS ‘usual’ pain), logistic




A total of 412 patients were enrolled in three con-
current multicenter studies in Sweden (n = 211, 27
centres), Denmark (n = 101, 12 centres, including
one in Iceland) and Norway (n = 100, 14 centres).
During the first treatment period, 30 patients discon-
tinued [due to ‘lost to follow-up’ (n = 11), lack of
pain relief (n = 7), withdrawn consent (n = 4), pro-
gression of concurrent diagnoses (n = 2), surgery/in-
jury of treated area (n = 2), incorrect enrolment
(n = 1), death due to cancer (n = 1), sensitivity to
capsaicin 8% patch (n = 1), hospitalization due to
pneumonia (n = 1)], leaving 382 patients for pri-
mary analysis. Re-treatment was initiated in 184
patients, but three patients discontinued, leaving 181
patients for analysis (Table S1). The population that
completed the first treatment period had a mean age
of 53.1 years, 41% of patients were male, and the
most common PNP diagnosis was partial peripheral
nerve injury (70%) (Table 2). Similar data were
observed in the population that completed the sec-
ond treatment period.
3.2 Pain intensity
Following first treatment, the overall group mean
NPRS ‘usual’ pain score was significantly reduced
from baseline to Weeks 2 through 8 (1.05; 95%
confidence interval: 1.27, 0.82; p < 0.001)
(Table 3). A total of 28% (n = 102) and 17%
(n = 61) of patients had a ≥30% and ≥50% reduc-
tion in mean NPRS ‘usual’ pain score, respectively,
from first treatment baseline to Weeks 2 through 8,
and 33% (n = 118) had a reduction of ≥2 units
(Table 4). Over the 12 weeks, the overall group
mean NPRS ‘usual’ pain score decreased from 6.27







Male 156 (41) 77 (43)
Female 226 (59) 104 (58)
Age, years
Mean (SD) 53.1 (16) 51.4 (15)
Median (min–max) 53 (18–88) 52 (18–85)
Certainty of PNP diagnosis, n (%)
Probable 127 (33) 62 (34)
Definite 255 (67) 119 (66)
PNP aetiology, n (%)
Partial peripheral nerve injury 266 (70) 125 (69)
Post-herpes zoster 51 (13) 22 (12)
Polyneuropathy 19 (5) 6 (3.3)
Other 46 (12) 28 (16)
Concomitant PNP medication, n (%)
Yes 205 (54) 94 (52)
No 177 (46) 87 (48)
Number of concomitant PNP medications (SD)
Mean (SD) 0.62 (0.78) 0.64 (0.80)
Median (min–max) 0.0 (0–4) 0.0 (0–4)
Size of treatment area, cm2
Mean (SD) 229.6 (195.9) 206.3 (178.7)
Median (min–max) 180 (3–1120) 160 (4–1000)
PNP, peripheral neuropathic pain; SD, standard deviation.
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[standard deviation (SD) 1.80, n = 382] at first treat-
ment baseline to 5.39 (SD 2.4, n = 368) (Fig. 1A).
After re-treatment, there was a significant reduc-
tion in the overall group mean NPRS ‘usual’ pain
from re-treatment baseline to Weeks 2 through 8
(0.75; 95% CI: 1.07, 0.42; p < 0.001). The pro-
portion of patients classified as ≥30% and ≥50%
responders after re-treatment [31% (n = 47) and
18% (n = 27), respectively] was similar to the
observed values after first treatment, and 26%
(n = 39) of patients had a reduction of ≥2 units. The
overall group mean NPRS ‘usual’ pain score
decreased from 5.18 (SD 2.32, n = 177) at re-treat-
ment baseline to 4.78 (SD 2.40, n = 162) over the
12 weeks (Fig. 1B). The proportion of ≥30% and
≥50% responders was similar from first treatment
baseline and re-treatment baseline to Weeks 2
through 12 (Table 4).
There were also reductions in the overall group
mean NPRS ‘highest’ and ‘lowest’ scores following
first treatment and re-treatment (Fig. 1A and B). A
reduction in mean NPRS ‘usual’ pain from first treat-
ment baseline and re-treatment baseline to Weeks 2
through 8 was reported in each PNP aetiology group
(Table 5). Overall, there were no significant differ-
ences in pain intensity reported between countries.
3.3 Patient global impression of change
Approximately half the patients reported an improve-
ment in overall health status at Week 12 after first
treatment; 21% (n = 80) reported either much
improvement or very much improvement (Table 6).
During the re-treatment period, 66% (n = 111) of
the patients reported an improvement and 44%
(n = 74) reported much improved or very much
improved. A worsening of health status or no change
was reported by 12% (n = 43) and 42% (n = 156) of
patients after first treatment, respectively, decreasing
to 7% (n = 12) and 27% (n = 45) after re-treatment.
3.4 EQ-5D-3L
At first treatment and re-treatment baseline, the
dimension with the lowest scores was pain/discom-
fort with 58% (n = 222) and 30% (n = 50) of
patients, respectively, reporting extreme problems.
The change in the overall group mean (SD) EQ-5D-
3L health score from first treatment baseline [0.331
(0.317)] to Week 2 was 0.148 utils, twofold the min-
imally important difference of 0.074 utils (Walters
and Brazier, 2005) (Fig. 2A), with 55% (n = 205) of
patients experiencing an improvement. At Week 2
following re-treatment, the health score increased by
0.126 utils with 40% (n = 65) experiencing an
improvement. Overall, the improvements in the
mean EQ-5D-3L health scores from first treatment
baseline and re-treatment baseline to Week 12 were
0.135 utils and 0.065 utils, respectively (Fig. 2A and
B), with 52% (n = 192) and 32% (n = 52) of
patients experiencing an improvement.
3.5 Willingness to undergo re-treatment
Of the 382 patients who completed the first treat-
ment period, 216 patients (57%) were willing to
Table 3 Change in the mean NPRS ‘usual’ score for the past 24 h
from baseline.a
Weeks 2 through 8 Weeks 2 through 12
First treatment (n = 361) (n = 381)
Mean (SD) 1.05 (2.91) 0.97 (2.04)
95% CI 1.27, 0.82 1.18, 0.77
p value ˂0.001 ˂0.001
Re-treatment (n = 151) (n = 169)
Mean (SD) 0.75 (2.00) 0.54 (1.87)
95% CI 1.07, 0.42 0.83, 0.26
p value ˂0.001 ˂0.001
CI, confidence interval; NPRS, Numerical Pain Rating Scale; SD, stan-
dard deviation.
A total of 382 and 181 patients received first treatment and re-treat-
ment, respectively.
aBaseline for re-treatment was the Week 12 assessment from first
treatment.
Table 4 Responders after each capsaicin 8% patch treatment.
Reduction in NPRS ‘usual’ pain
≥30% ≥50% ≥2 units










109 (29 [24, 33]) 62 (16 [13, 20]) 112 (29 [25, 34])










45 (27 [21, 34]) 20 (12 [8, 18]) 28 (17 [12, 23])
CI, confidence interval; NPRS ‘usual’ pain, Numeric Pain Rating Scale
‘usual pain in the last 24 h’.
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Figure 1 Change in mean pain intensity measured by Numerical Pain Rating Scale (NPRS) after (A) first treatment and (B) re-treatment with cap-
saicin 8% patch. NPRS was assessed for ‘usual level of pain for the past 24 h’, pain intensity ‘right now’ and the ‘highest’ and ‘lowest’ pain scores.
*Mean (SD).
Table 5 Change in mean NPRS ‘usual’ pain score, from baselinea to Weeks 2 and 8, according to PNP aetiology.
Mean change in NPRS
‘usual’ pain (95% CI)








First treatment 0.98 (1.23, 0.71) 1.03 (1.59, 0.47) 0.57 (1.50, 0.35) 1.66 (2.26, 1.05)
Re-treatment 0.73 (1.08, 0.38) 0.62 (1.50, 0.25) 0.44 (1.91, 1.03) 0.98 (1.73, 0.23)
CI, confidence interval; NPRS, Numerical Pain Rating Scale; PNP, peripheral neuropathic pain.
aBaseline for re-treatment was the Week 12 assessment from first treatment.
bNumber of patients in each aetiology group at baseline.
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receive a second treatment (Table 7). The primary
reason for treatment discontinuation was unsatisfac-
tory pain relief (73%; n = 137). Re-treatment was
initiated for 194 patients (51%), with 181 patients
(47%) completing the re-treatment period. In 55%
(n = 100) of patients who received re-treatment,
patch application was performed directly after the
first treatment period (on the final assessment day).
Table 6 Summary of the answers to the Patient Global Impression of Change after first treatment and re-treatment with capsaicin 8% patch.
Week 1 Week 2 Week 4 Week 8 Week 12
First treatment, n (%) (n = 267) (n = 278) (n = 266) (n = 215) (n = 374)
I feel very much worse 6 (2) 2 (1) 4 (2) 2 (1) 4 (1)
I feel much worse 6 (2) 7 (3) 9 (3) 6 (3) 6 (2)
I feel slightly worse 25 (9) 25 (9) 18 (7) 21 (10) 33 (9)
I feel no change 86 (32) 99 (36) 83 (31) 82 (38) 156 (42)
I feel slightly improved 89 (33) 85 (31) 85 (32) 51 (24) 95 (25)
I feel much improved 28 (11) 39 (14) 36 (14) 30 (14) 48 (13)
I feel very much improved 27 (10) 21 (76) 31 (12) 23 (11) 32 (9)
Re-treatment, n (%) (n = 131) (n = 108) (n = 103) (n = 82) (n = 169)
I feel very much worse 1 (1) 0 0 0 0
I feel much worse 3 (2) 1 (1) 3 (3) 0 3 (2)
I feel slightly worse 6 (5) 3 (3) 3 (3) 1 (1) 9 (5)
I feel no change 19 (15) 12 (11) 23 (22) 17 (21) 45 (27)
I feel slightly improved 43 (33) 40 (37) 29 (28) 23 (28) 37 (22)
I feel much improved 27 (21) 28 (26) 21 (20) 24 (29) 42 (25)
I feel very much improved 32 (24) 24 (22) 24 (23) 17 (21) 32 (19)
A
B
Figure 2 Mean values for EQ-5D-3L health scores by visit after the first treatment (A) and re-treatment (B). *Mean (SD).
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After re-treatment, 128 patients (71%) were willing
to receive an additional (third) treatment. The med-
ian time between first treatment and re-treatment
was 100 (range 43–289) days.
3.6 Change in size of painful area
At Week 2, 34% (n = 85) of the patients reported a
decrease in the size of the painful area after first
treatment, while following re-treatment, 44%
(n = 42) of patients reported a reduction at Week 2.
At Week 12 following treatment and re-treatment, a
decrease in the size of the painful area from baseline
and re-treatment baseline was reported in 28%
(n = 99) and 35% (n = 55) of patients, respectively.
3.7 Tolerability
Immediately after application, 157 patients (41%)
presented with a mild application site reaction, 148
(39%) a moderate application site reaction and 43
(11%) a severe application site reaction. Thirty-
seven (10%) patients required rescue medication for
application site reactions, while 201 patients (52%)
required rescue treatment for treatment-induced
pain. During the week following treatment, the pro-
portion of patients reporting moderate and severe
application site reactions decreased to 7% (n = 27).
In addition, the maximum pain intensity (mean
NPRS pain ‘right now’ score) due to capsaicin 8%
patch treatment, at the group level, decreased from
5.7 (SD 2.2) at first treatment baseline (after applica-
tion) to 4.7 (SD 2.6) at Week 1 (Fig. 1A).
Following re-treatment application, 72 patients
(40%) showed a mild application site reaction, 57
(32%) a moderate reaction and 21 patients (12%) a
severe reaction. Rescue medication was required by
14 (8%) patients for application site reactions and by
87 patients (48%) for treatment-induced pain. At
Week 1 following re-treatment, moderate and severe
application site reactions were observed in only 6%
(n = 10) of patients and the maximum pain intensity
(mean NPRS ‘pain right now’ score) due to capsaicin
8% patch treatment decreased from 5.0 (SD 2.6) to
3.6 (SD 2.6) at the group level (Fig. 1B).
3.8 Concomitant medication due to PNP
There was no change in the overall use of concomi-
tant medication for PNP from first treatment baseline
(47%, n = 382) to Week 12 (49%, n = 381)
(Table 8). The most common form of additional
medication at baseline was over-the-counter anal-
gesics, which were used by 95 patients (25%) at
Week 2 and by 131 patients (34%) at Week 12.
There was also no notable changes in the overall use
of concomitant medication due to PNP from re-treat-
ment baseline (48%, n = 181) to Week 12 (52%,
n = 178).






Patient agrees to re-treatment
No, absolutely not
Unsure 40 (10) 24 (13)
Yes, definitely 216 (57) 128 (71)
Patient’s reason no or unsure about re-treatment
Not relevant, no longer
have pain due to PNP
6 (2) 4 (2)
Unsatisfactory pain relief 132 (35) 38 (21)
Initial adverse event, pain
due to patch
12 (3) 1 (1)
Other reason 14 (4) 8 (4)
Patient will receive re-treatment
No 187 (49) 55 (30)
Yes 194 (51) 126 (70)
Physician’s reason for no or unsure about re-treatment
Patient not interested in
re-treatment
16 (4) 3 (2)
Not relevant, no longer have
pain due to PNP
15 (4) 5 (3)
Unsatisfactory pain relief 137 (36) 39 (22)
Initial adverse event, application
site reaction due to patch
1 (˂0.5%) 0
Initial adverse event, pain
due to patch
4 (1) 1 (1)
Other reason 14 (4) 7 (4)
PNP, peripheral neuropathic pain.


















45 (12) 56 (15) 30 (17) 31 (17)
Combinationa 22 (6) 26 (7) 12 (7) 12 (7)
Opioids 11 (3) 18 (5) 9 (5) 10 (6)
Local anaesthetics 7 (2) 11 (3) 6 (3) 6 (3)
Antidepressants 10 (3) 14 (4) 5 (3) 7 (4)
Anticonvulsants 6 (2) 8 (2) 4 (2) 4 (2)
Other 18 (5) 22 (6) 8 (4) 11 (6)
aFixed-dose combination medication containing active agents from
more than one pain medication subgroup.
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4. Discussion
This study demonstrates that in Scandinavian clinical
practice, the capsaicin 8% patch provided effective
pain relief in a proportion of patients with PNP and
was generally well tolerated. The overall group of
patients had a significant reduction in NPRS ‘usual’
pain from first treatment baseline and re-treatment
baseline to Weeks 2 through 8 along with clear
improvements in PGIC and HRQoL throughout the
study. The majority of application site reactions
diminished within a week of treatment, and over
half of patients treated were willing to undergo re-
treatment.
Aligned with previous clinical trials using the
same patch, a reduction in mean NPRS ‘usual’ pain
was reported at Week 1 following treatment and
was sustained to the final visit (Backonja et al.,
2008; Simpson et al., 2008; Haanpaa et al., 2016).
Overall, 28% and 31% of patients reported a ≥30%
decrease in pain from first treatment baseline and
re-treatment baseline to Weeks 2 through 8, respec-
tively, and significant reductions (1.05 and 0.75,
respectively) (p ˂ 0.001) in mean NPRS ‘usual’ pain
were observed. In addition to a reduction in pain,
patients also experienced a decrease in the size of
the estimated painful area at the group level, with
28% of patients reporting a decrease over 12 weeks.
Although improvements in pain intensity and the
proportion of ≥30% responders after one treatment
are lower than previously reported in other cap-
saicin 8% patch trials (2.00 to 2.37 and 42% to
56%, respectively) (Backonja et al., 2008; Irving
et al., 2011; Clifford et al., 2012; Haanpaa et al.,
2016), there is a similar trend in the data. Also, the
heterogeneous patient population from a diagnostic
perspective may have included subgroups of patients
less susceptible to respond to this type of treatment.
For example, in another real-world study of the
capsaicin 8% patch that included seven European
countries, patients with post-operative and post-
traumatic neuropathic pain had less improvement in
pain over 8 weeks compared with patients with
other aetiologies including postherpetic neuralgia
and neuropathic back pain (Mankowski et al.,
2017). Direct comparisons to other studies are not
possible due to differences in trial design (i.e. real-
world vs. controlled study, timing of study visits,
patient population).
In addition to pain relief, the overall health status
at the group level, as measured by PGIC, was also
improved, with over 50% of patients reporting an
improvement (slight, much, very much) at Week 1
following first treatment. This result was sustained
over the 12 weeks and after re-treatment with a
higher proportion of patients reporting a ‘much or
very much’ improvement. This may be due to the
overall further reduction in pain intensity after re-
treatment. In addition, improvements in HRQoL
were also observed early after treatment from first
treatment baseline and re-treatment baseline to
Week 1. From first treatment baseline to Week 2,
the change in EQ-5D-3L health score at the group
level (0.148 utils) indicates a clinically meaningful
improvement in quality of life (Walters and Brazier,
2005) with 52% of patients experiencing an
improvement. Together, these results are in agree-
ment with a European real-world study of the cap-
saicin 8% patch where 63% of patients had an
improvement in PGIC at Week 2, and the EQ-5D-3L
health increased by 0.199 utils from baseline to
Week 2 (Mankowski et al., 2017).
In general, the capsaicin 8% patch was well toler-
ated, and in most cases, adverse application site reac-
tions diminished within a week after treatment.
Interestingly, on treatment visits, reported mean
NPRS ‘usual’ pain was higher than treatment-related
pain (NPRS ‘pain now’ score). The proportion of
patients with severe application site reactions corre-
sponded well with those needing rescue measures for
the treatment-related application site reactions.
Although only a third of patients experienced ≥30%
reduction in pain, over half of patients were willing to
receive a second treatment with the patch, with only
3% of patients discontinuing treatment due to an
adverse drug reaction. Over half of patients willing to
undergo re-treatment had their second capsaicin 8%
patch application at their final visit (90 days post-
treatment). About three-quarters of the patients who
completed re-treatment were willing to continue to a
third treatment. These results suggest that despite
application site reactions, a large number of patients
were willing to undergo re-treatment.
Strengths of the present study include a real-world
setting, inclusion of patients with different PNP aeti-
ologies, assessment of re-treatment with the cap-
saicin 8% patch and the assessment of patients’
willingness to undergo re-treatment. As this was a
pragmatic study, it was not designed to determine
treatment efficacy. Other limitations included a lack
of systematic collection of data for adverse effects
and concomitant medications. In addition, the size of
the painful area, assessed through rough estimations
by patients, could have been assessed more precisely
during study visits, and the patient’s treatment satis-
faction was not included in the protocol. Moreover,
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the patches may not have covered the entire painful
area in some patients with polyneuropathy, and for
patients who did not receive re-treatment on the
final visit after first treatment, it would have been
more accurate to perform re-treatment baseline
assessments at the re-treatment visit (before patch
application).
In conclusion, capsaicin 8% patch treatment in
routine clinical practice led to moderate, yet statisti-
cally significant, improvements in pain relief with
approximately a third of patients experiencing ≥30%
reduction in pain after first and second treatment and
over half of patients willing to have further treat-
ment. In addition, the proportion of patients report-
ing an improvement in their health status almost
doubled with re-treatment with a large number of
patients reporting improvements in quality of life.
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